Percentage (number) of patients with clinically important problems in the EORTC QLQ-C30 functioning and symptom subscales within the total European CAR-T cohort and per subgroup
| EORTC QLQ-C30 functioning/symptom subscale . | Total European CAR-T cohort (N = 389) . | Sex . | Age . | Time since CAR-T infusion . | Admission to ICU . | Neurological side effects . | Disease progression after CAR-T therapy . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female (n = 142) . | Male (n = 247) . | >70 years (n = 68) . | ≤70 years (n = 321) . | ≤3 months (n = 64) . | 4-12 months (n = 106) . | >1 year to 2 years (n = 97) . | ≥2 years (n = 122) . | Yes (n = 93) . | No (n = 296) . | Yes (n = 163) . | No (n = 213) . | Yes (n = 76) . | No (n = 284) . | ||
| Physical functioning | 40.9% (159) | 49.3%∗(70) | 36.0%∗(89) | 48.5%∗(33) | 39.3%∗(126) | 45.3% (29) | 50.0% (53) | 43.3% (97) | 28.7% (35) | 44.1% (41) | 39.9% (118) | 47.2%∗(77) | 35.7%∗(76) | 51.3% (39) | 37.3% (106) |
| Cognitive functioning | 34.4% (134) | 36.6% (52) | 33.2% (82) | 32.4% (22) | 34.9% (112) | 29.7% (19) | 40.6% (43) | 35.1% (34) | 31.1% (38) | 37.6% (35) | 33.4% (99) | 44.8%∗(73) | 24.9%∗(53) | 35.5% (27) | 33.5% (95) |
| Emotional functioning | 29.6% (115) | 32.4% (46) | 27.9% (69) | 27.9% (19) | 29.9% (96) | 23.4% (15) | 36.8% (39) | 33.0% (32) | 23.8% (29) | 29.0% (27) | 29.7% (88) | 33.7% (55) | 25.4% (54) | 35.5% (27) | 28.5% (81) |
| Role functioning | 22.1% (86) | 20.4% (29) | 23.1% (57) | 16.2% (11) | 23.4% (75) | 29.7%∗(19) | 26.4% (28) | 25.8% (25) | 11.5%∗(14) | 29.0% (27) | 19.9% (59) | 24.5% (40) | 19.2% (41) | 26.3% (20) | 20.4% (58) |
| Social functioning | 20.1% (78) | 21.8% (31) | 19.0% (47) | 19.1% (13) | 20.2% (65) | 18.8% (12) | 19.8% (21) | 27.8% (27) | 14.8% (18) | 23.7% (22) | 18.9% (56) | 26.4%∗(43) | 14.6%∗(31) | 21.1% (16) | 20.1% (57) |
| Financial difficulties | 28.0% (109) | 22.5% (32) | 31.2% (77) | 8.8%∗(6) | 32.1%∗(103) | 31.3% (20) | 28.3% (30) | 26.8% (26) | 27.0% (33) | 31.2% (29) | 27.0% (80) | 32.5% (53) | 24.4% (52) | 25.0% (19) | 28.2% (80) |
| Fatigue | 28.3% (110) | 26.1% (37) | 29.6% (73) | 29.4% (20) | 28.0% (90) | 31.3% (20) | 33.0% (35) | 30.9% (30) | 20.5% (25) | 32.3% (30) | 27.0% (80) | 31.3% (51) | 26.3% (56) | 31.6% (24) | 25.7% (73) |
| Nausea/vomiting | 15.4% (60) | 16.9% (24) | 14.6% (36) | 11.8% (8) | 16.2% (52) | 12.5% (8) | 22.6% (24) | 15.5% (15) | 10.7% (13) | 14.0% (13) | 15.9% (47) | 17.2% (28) | 13.6% (29) | 25.0%∗(19) | 12.7%∗(36) |
| Pain | 32.9% (128) | 38.7%∗(55) | 29.6%∗(73) | 33.8% (23) | 32.7% (105) | 21.9% (14) | 37.7% (40) | 36.1% (35) | 32.0% (39) | 33.3% (31) | 32.8% (97) | 35.0% (57) | 31.5% (67) | 35.5% (27) | 33.5% (95) |
| Dyspnea | 37.5% (146) | 32.4% (46) | 40.5% (100) | 39.7% (27) | 37.1% (119) | 45.3% (29) | 42.5% (45) | 37.1% (36) | 29.5% (36) | 35.5% (33) | 38.2% (113) | 40.5% (66) | 35.2% (75) | 42.1% (32) | 34.2% (97) |
| Insomnia | 19.0% (74) | 23.9%∗(34) | 16.2%∗(40) | 20.6% (14) | 18.7% (60) | 17.2% (11) | 25.5% (27) | 17.5% (17) | 15.6% (19) | 20.4% (19) | 18.6% (55) | 22.1% (36) | 16.0% (34) | 22.4% (17) | 18.0% (51) |
| Appetite loss† | 3.6% (14) | 3.5% (5) | 3.6% (9) | 5.9% (4) | 3.1% (10) | 3.1% (2) | 6.6% (7) | 4.1% (4) | 0.8% (1) | 3.2% (3) | 3.7% (11) | 3.7% (6) | 3.3% (7) | 6.6% (5) | 2.5% (7) |
| Constipation† | 3.9% (15) | 3.5% (5) | 4.0% (10) | 7.4% (5) | 3.1% (10) | 1.6% (1) | 4.7% (5) | 5.2% (5) | 3.3% (4) | 3.2% (3) | 4.1% (12) | 4.9% (8) | 3.3% (7) | 7.9% (6) | 3.2% (9) |
| Diarrhea | 20.8% (81) | 24.6% (35) | 18.6% (46) | 20.6% (14) | 20.9% (67) | 26.6% (17) | 22.6% (24) | 20.6% (20) | 16.4% (20) | 20.4% (19) | 20.9% (62) | 22.7% (37) | 18.8% (40) | 25.0% (19) | 18.0% (51) |
| EORTC QLQ-C30 functioning/symptom subscale . | Total European CAR-T cohort (N = 389) . | Sex . | Age . | Time since CAR-T infusion . | Admission to ICU . | Neurological side effects . | Disease progression after CAR-T therapy . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female (n = 142) . | Male (n = 247) . | >70 years (n = 68) . | ≤70 years (n = 321) . | ≤3 months (n = 64) . | 4-12 months (n = 106) . | >1 year to 2 years (n = 97) . | ≥2 years (n = 122) . | Yes (n = 93) . | No (n = 296) . | Yes (n = 163) . | No (n = 213) . | Yes (n = 76) . | No (n = 284) . | ||
| Physical functioning | 40.9% (159) | 49.3%∗(70) | 36.0%∗(89) | 48.5%∗(33) | 39.3%∗(126) | 45.3% (29) | 50.0% (53) | 43.3% (97) | 28.7% (35) | 44.1% (41) | 39.9% (118) | 47.2%∗(77) | 35.7%∗(76) | 51.3% (39) | 37.3% (106) |
| Cognitive functioning | 34.4% (134) | 36.6% (52) | 33.2% (82) | 32.4% (22) | 34.9% (112) | 29.7% (19) | 40.6% (43) | 35.1% (34) | 31.1% (38) | 37.6% (35) | 33.4% (99) | 44.8%∗(73) | 24.9%∗(53) | 35.5% (27) | 33.5% (95) |
| Emotional functioning | 29.6% (115) | 32.4% (46) | 27.9% (69) | 27.9% (19) | 29.9% (96) | 23.4% (15) | 36.8% (39) | 33.0% (32) | 23.8% (29) | 29.0% (27) | 29.7% (88) | 33.7% (55) | 25.4% (54) | 35.5% (27) | 28.5% (81) |
| Role functioning | 22.1% (86) | 20.4% (29) | 23.1% (57) | 16.2% (11) | 23.4% (75) | 29.7%∗(19) | 26.4% (28) | 25.8% (25) | 11.5%∗(14) | 29.0% (27) | 19.9% (59) | 24.5% (40) | 19.2% (41) | 26.3% (20) | 20.4% (58) |
| Social functioning | 20.1% (78) | 21.8% (31) | 19.0% (47) | 19.1% (13) | 20.2% (65) | 18.8% (12) | 19.8% (21) | 27.8% (27) | 14.8% (18) | 23.7% (22) | 18.9% (56) | 26.4%∗(43) | 14.6%∗(31) | 21.1% (16) | 20.1% (57) |
| Financial difficulties | 28.0% (109) | 22.5% (32) | 31.2% (77) | 8.8%∗(6) | 32.1%∗(103) | 31.3% (20) | 28.3% (30) | 26.8% (26) | 27.0% (33) | 31.2% (29) | 27.0% (80) | 32.5% (53) | 24.4% (52) | 25.0% (19) | 28.2% (80) |
| Fatigue | 28.3% (110) | 26.1% (37) | 29.6% (73) | 29.4% (20) | 28.0% (90) | 31.3% (20) | 33.0% (35) | 30.9% (30) | 20.5% (25) | 32.3% (30) | 27.0% (80) | 31.3% (51) | 26.3% (56) | 31.6% (24) | 25.7% (73) |
| Nausea/vomiting | 15.4% (60) | 16.9% (24) | 14.6% (36) | 11.8% (8) | 16.2% (52) | 12.5% (8) | 22.6% (24) | 15.5% (15) | 10.7% (13) | 14.0% (13) | 15.9% (47) | 17.2% (28) | 13.6% (29) | 25.0%∗(19) | 12.7%∗(36) |
| Pain | 32.9% (128) | 38.7%∗(55) | 29.6%∗(73) | 33.8% (23) | 32.7% (105) | 21.9% (14) | 37.7% (40) | 36.1% (35) | 32.0% (39) | 33.3% (31) | 32.8% (97) | 35.0% (57) | 31.5% (67) | 35.5% (27) | 33.5% (95) |
| Dyspnea | 37.5% (146) | 32.4% (46) | 40.5% (100) | 39.7% (27) | 37.1% (119) | 45.3% (29) | 42.5% (45) | 37.1% (36) | 29.5% (36) | 35.5% (33) | 38.2% (113) | 40.5% (66) | 35.2% (75) | 42.1% (32) | 34.2% (97) |
| Insomnia | 19.0% (74) | 23.9%∗(34) | 16.2%∗(40) | 20.6% (14) | 18.7% (60) | 17.2% (11) | 25.5% (27) | 17.5% (17) | 15.6% (19) | 20.4% (19) | 18.6% (55) | 22.1% (36) | 16.0% (34) | 22.4% (17) | 18.0% (51) |
| Appetite loss† | 3.6% (14) | 3.5% (5) | 3.6% (9) | 5.9% (4) | 3.1% (10) | 3.1% (2) | 6.6% (7) | 4.1% (4) | 0.8% (1) | 3.2% (3) | 3.7% (11) | 3.7% (6) | 3.3% (7) | 6.6% (5) | 2.5% (7) |
| Constipation† | 3.9% (15) | 3.5% (5) | 4.0% (10) | 7.4% (5) | 3.1% (10) | 1.6% (1) | 4.7% (5) | 5.2% (5) | 3.3% (4) | 3.2% (3) | 4.1% (12) | 4.9% (8) | 3.3% (7) | 7.9% (6) | 3.2% (9) |
| Diarrhea | 20.8% (81) | 24.6% (35) | 18.6% (46) | 20.6% (14) | 20.9% (67) | 26.6% (17) | 22.6% (24) | 20.6% (20) | 16.4% (20) | 20.4% (19) | 20.9% (62) | 22.7% (37) | 18.8% (40) | 25.0% (19) | 18.0% (51) |
ICU, intensive care unit; N, number.
Statistically significant differences are indicated with an asterisk and in bold (P values of <.05 considered statistically significant).
Statistical significance testing using multivariable models was not conducted for constipation and appetite loss due to the limited number of events.